Evidence map›Paper›PMID 31291801›Full record

ArticleJournal of the American Heart Association2019

Incremental Value of Implantable Cardiac Device Diagnostic Variables Over Clinical Parameters to Predict Mortality in Patients With Mild to Moderate Heart Failure.

Jaimie Manlucu, Vinod Sharma, Jodi Koehler, Eduardo N Warman, George A Wells, Lorne J Gula, Raymond Yee, Anthony S Tang

Registry-linked trialAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00251251 (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00251251 nacompletednot on this map

Resynchronization/Defibrillation for Ambulatory Heart Failure Trial

TypeinterventionalSponsorOttawa Heart Institute Research CorporationRan2003 to 2011Enrolled1,798ConditionsHeart Failure, CongestiveArmsOptimal Medical Therapy plus ICD, Optimal Medical Therapy plus CRT/ICD
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jaimie Manlucu1 Western University London Ontario Canada.
Vinod Sharma2 Medtronic, Inc Minneapolis MN.
Jodi Koehler2 Medtronic, Inc Minneapolis MN.
Eduardo N Warman2 Medtronic, Inc Minneapolis MN.
George A Wells3 University of Ottawa Heart Institute Ottawa Ontario Canada.
Lorne J Gula1 Western University London Ontario Canada.
Raymond Yee1 Western University London Ontario Canada.
Anthony S Tang1 Western University London Ontario Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Heart failure remains a leading cause of morbidity and mortality. Clinical prediction models provide suboptimal estimates of mortality in this population. We sought to determine the incremental value of implantable device diagnostics over clinical prediction models for mortality. Methods and Results RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial) patients with implanted devices capable of device diagnostic monitoring were included, and demographic and clinical parameters were used to compute Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) heart failure risk scores. Patients were classified according to MAGGIC score into low (0-16), intermediate (17-24), or high (>24) risk groups. Mortality was evaluated from 6 months postimplant in accordance with the RAFT protocol. In a subset of 1036 patients, multivariable analysis revealed that intermediate and high MAGGIC scores, fluid index, atrial fibrillation, and low activity flags were independent predictors of mortality. A device-integrated diagnostic parameter that included a fluid index flag and either a positive atrial fibrillation flag or a positive activity flag was able to significantly differentiate higher from lower risk for mortality in the intermediate MAGGIC cohort. The effect was more pronounced in the high-risk MAGGIC cohort, in which device-integrated diagnostic-positive patients had a shorter time to death than those who were device-integrated diagnostic negative. Conclusions Device diagnostics using a combination of fluid index trends, atrial fibrillation burden, and patient activity provide significant incremental prognostic value over clinical heart failure prediction scores in higher-risk patients. This suggests that combining clinical and device diagnostic parameters may lead to models with better predictive power. Whether this risk is modifiable with early medical intervention would warrant further studies. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT00251251.

Indexed as

Cardiac Resynchronization Therapy DevicesDefibrillators, ImplantableMortalityAgedAtrial FibrillationCardiac Resynchronization TherapyElectric CountershockFemaleHeart FailureHeart RateHumansMaleMiddle AgedRisk AssessmentRisk FactorsStroke Volumedevice diagnosticsheart failureimplantable cardioverter‐defibrillatormodelmortalityprognostic factor

Identifiers

PMID31291801
PMCPMC6662119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.